Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | Herzuma? | Company | Celltrion, Inc. |
|---|---|---|---|
| Classification | Biosimilar | Active Ingredient | Trastuzumab |
| Reference Product | Herceptin | Approval Date | 2014 |
| Indication | (150mg / 440mg) Early breast cancer, metastatic breast cancer, metastatic gastric cancer | ||
| Description |
A humanized monoclonal antibody(mAb) biosimilar approved by MFDS in 2014.
Herzuma is an antibody against epidermal growth factor (EGF) receptor 2 (HER2; ErbB2; neu) to treat early breast cancer, metastatic breast cancer, metastatic gastric cancer. |
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.